1. Better survival is observed in cervical cancer patients positive for specific anti-glycan antibodies and receiving brachytherapy
- Author
-
Manual Alvarez, Peng George Wang, Daron G. Ferris, Richard D. Cummings, Wenbo Zhi, Sharad Purohit, Paul Minh Huy Tran, Boying Dun, Lynn Kim Hoang Tran, Diane Hopkins, John J. Wallbillich, David Mysona, and Jin-Xiong She
- Subjects
Adult ,0301 basic medicine ,Oncology ,medicine.medical_specialty ,Glycan ,medicine.medical_treatment ,Brachytherapy ,External beam radiation ,Uterine Cervical Neoplasms ,Article ,Antibodies ,03 medical and health sciences ,0302 clinical medicine ,Internal medicine ,medicine ,Humans ,Progression-free survival ,Stage (cooking) ,Glucans ,Aged ,Neoplasm Staging ,Cervical cancer ,biology ,Proportional hazards model ,business.industry ,Age Factors ,Obstetrics and Gynecology ,Middle Aged ,medicine.disease ,Progression-Free Survival ,Survival Rate ,030104 developmental biology ,030220 oncology & carcinogenesis ,biology.protein ,Female ,Antibody ,business - Abstract
OBJECTIVE: To measure anti-glycan antibodies (AGA) in cervical cancer (CC) patient sera and assess their effect on therapeutic outcome. PATIENTS AND METHODS: Serum AGA was measured in 276 stage II and 292 stage III Peruvian CC patients using a high content and throughput Luminex multiplex glycan array (LMGA) containing 177 glycans. Association with disease-specific survival (DSS) and progression free survival (PFS) were analyzed using Cox regression. RESULTS: AGAs were detected against 50 (28.3%) of the 177 glycans assayed. Of the 568 patients, 84.5% received external beam radiation therapy (EBRT) plus brachytherapy (BT), while 15.5% only received EBRT. For stage-matched patients (Stage III), receiving EBRT alone was significantly associated with worse survival (HR 6.4, p < 0.001). Stage III patients have significantly worse survival than Stage II patients after matching for treatment (HR = 2.8 in EBRT+BT treatment group). Furthermore, better PFS and DSS were observed in patients positive for AGA against multiple glycans belonging to the blood group H, Lewis, Ganglio, Isoglobo, lacto and sialylated tetrarose antigens (best HR = 0.49, best p = 0.0008). CONCLUSIONS: Better PFS and DSS are observed in cervical cancer patients that are positive for specific antiglycan antibodies and received brachytherapy.
- Published
- 2020